KTTA - Pasithea Therapeutics Corp. Stock Price, Fair Value and News

6.60USD+0.10 (+1.54%)Delayed as of 17 May 2024, 12:38 pm ET

Market Summary

USD6.60+0.10

Delayedas of 17 May 2024, 12:38 pm

1.54%

KTTA Stock Price

View Fullscreen

KTTA RSI Chart

KTTA Valuation

Market Cap

6.8M

Price/Earnings (Trailing)

-0.42

Price/Sales (Trailing)

16.33

EV/EBITDA

0.33

Price/Free Cashflow

-0.49

KTTA Price/Sales (Trailing)

KTTA Profitability

EBT Margin

-3876.75%

Return on Equity

-81.9%

Return on Assets

-72.67%

Free Cashflow Yield

-205.18%

KTTA Fundamentals

KTTA Revenue

Revenue (TTM)

415.4K

Rev. Growth (Yr)

-28.2%

Rev. Growth (Qtr)

31.19%

KTTA Earnings

Earnings (TTM)

-16.3M

Earnings Growth (Yr)

-9.13%

Earnings Growth (Qtr)

23.52%

Breaking Down KTTA Revenue

52 Week Range

6.60

(Low)(High)

Last 7 days

-15.4%

Last 30 days

-10.3%

Last 90 days

-10.0%

Trailing 12 Months

-4.4%

How does KTTA drawdown profile look like?

KTTA Financial Health

Current Ratio

5.35

KTTA Investor Care

Buy Backs (1Y)

20.14%

Diluted EPS (TTM)

-0.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q3	Q4
2024	0	0	0
2023	462.8K	439.1K	415.4K
2022	0	0	486.6K
2021	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Pasithea Therapeutics Corp.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 02, 2023	steinman lawrence	bought	12,930	0.431	30,000	-
Nov 28, 2022	steinman lawrence	acquired	4,900	0.98	5,000	-
Nov 25, 2022	marques tiago	acquired	2,060	1.03	2,000	chief executive officer
Nov 23, 2022	marques tiago	acquired	7,260	1.00751	7,206	chief executive officer
Nov 22, 2022	steinman lawrence	acquired	4,950	0.99	5,000	-
Nov 17, 2022	dumesnil simon	acquired	42,400	1.06	40,000	-
Nov 15, 2022	dumesnil simon	acquired	10,700	1.07	10,000	-
Oct 26, 2022	steinman lawrence	acquired	5,500	1.1	5,000	-
Oct 21, 2022	marques tiago	acquired	5,356	1.0712	5,000	chief executive officer
Oct 17, 2022	delaney david	bought	1,110	1.11	1,000	-

Which funds bought or sold KTTA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	ADAR1 Capital Management, LLC	new	-	200,804	200,804	0.05%
May 15, 2024	ARMISTICE CAPITAL, LLC	unchanged	-	-17,385	615	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-4,587	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	9,751	9,751	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-2,000	-	-%
May 15, 2024	Royal Bank of Canada	new	-	2,000	2,000	-%
May 15, 2024	CITADEL ADVISORS LLC	added	1,915	-74.00	162	-%
May 14, 2024	NORTHERN TRUST CORP	sold off	-100	-17,417	-	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	sold off	-100	-12,000	-	-%
May 13, 2024	UBS Group AG	new	-	-	-	-%

Are Funds Buying or Selling KTTA?

Are funds buying KTTA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KTTA

No. of Funds

Unveiling Pasithea Therapeutics Corp.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jun 08, 2023	steinman lawrence	6.0%	1,577,174	SC 13D
Feb 15, 2023	manning paul b	11.3%	3,408,696	SC 13G/A
Jan 13, 2023	khire uday	4.6%	1,228,108	SC 13G/A
Jan 10, 2023	camac fund, lp	0%	0	SC 13D/A
Dec 14, 2022	camac fund, lp	1%	191,321	SC 13D/A
Nov 01, 2022	camac fund, lp	1%	191,321	SC 13D/A
Oct 20, 2022	khire uday	5.0%	1,472,662	SC 13G
Sep 06, 2022	camac fund, lp	1%	191,321	SC 13D/A
Sep 01, 2022	camac fund, lp	1%	191,321	SC 13D/A
Jul 28, 2022	camac fund, lp	1%	191,321	SC 13D/A

Recent SEC filings of Pasithea Therapeutics Corp.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
Apr 05, 2024	4/A	Insider Trading
Apr 05, 2024	4/A	Insider Trading
Apr 05, 2024	4/A	Insider Trading
Apr 05, 2024	4/A	Insider Trading
Apr 05, 2024	4/A	Insider Trading
Apr 05, 2024	4/A	Insider Trading
Apr 05, 2024	4/A	Insider Trading
Apr 02, 2024	EFFECT	EFFECT

Peers (Alternatives to Pasithea Therapeutics Corp.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Pasithea Therapeutics Corp. News

Latest updates

Pasithea Therapeutics Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-100.0%	-	172,825	131,740	186,226	240,712	218,608	13,581	1,609,054	3,204,527	4,800,000
Gross Profit	-	-	-	-	-	-	132,143	-1,520	721	-	-
S&GA Expenses	27.5%	2,291,646	1,797,234	2,164,560	2,116,266	2,656,305	2,576,802	2,611,559	2,078,878	1,954,044	1,273,600
R&D Expenses	-47.8%	1,749,128	3,351,548	1,624,766	1,096,286	-	1,278,922	-	-	-	-
EBITDA Margin	-3.8%	-38.72	-37.29	-33.05	-29.59	-24.09	-	-	-	-	-
Interest Expenses	-	-	-	-	6,388	-	-	-	-	-	-508
Earnings Before Taxes	23.3%	-3,860,840	-5,031,264	-3,612,590	-3,265,810	-4,053,404	-4,191,041	-2,189,859	-1,293,581	630,143	-1,526,108
EBT Margin	-3.8%	-38.77	-37.33	-33.09	-29.60	-24.10	-	-	-	-	-
Net Income	23.5%	-3,860,840	-5,048,159	-3,612,590	-3,537,679	-5,117,688	-4,586,130	-2,658,394	-1,574,240	630,143	-1,526,108
Net Income Margin	-2.0%	-39.21	-38.43	-36.51	-34.35	-28.64	-	-	-	-	-
Free Cashflow	-31.2%	-4,321,085	-3,294,308	-3,215,186	-3,256,166	-3,278,113	-4,627,080	-1,942,366	-2,154,109	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet												(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-14.2%	22,408	26,117	30,657	38,149	42,045	45,180	49,608	53,028	51,079	53,321	21,042	-
Current Assets	-21.0%	13,193	16,692	20,771	28,037	31,113	34,077	44,469	48,614	50,950	53,300	21,034	248
Cash Equivalents	-26.3%	12,009	16,300	19,585	26,648	29,914	33,088	42,380	47,896	50,321	52,902	20,565	244
Net PPE	-3.3%	136	141	146	173	175	125	341	170	129	20.00	9.00	-
Goodwill	0%	1,263	1,263	1,263	1,263	1,263	1,263	3,854	3,833	-	-	-	-
Liabilities	-7.1%	2,525	2,718	2,284	2,559	2,910	2,682	2,819	1,554	1,101	1,900	4,567	-
Current Liabilities	-6.3%	2,467	2,634	2,044	2,229	2,122	1,878	1,514	950	434	447	528	7.00
Shareholder's Equity	-15.0%	19,883	23,398	28,374	35,590	39,135	42,498	46,789	51,322	49,977	51,421	16,475	241
Retained Earnings	-10.9%	-39,179	-35,318	-30,270	-26,657	-22,894	-19,356	-11,033	-6,447	-3,788	-2,214	-2,844	-40.98
Additional Paid-In Capital	0.6%	59,068	58,722	58,634	62,233	62,015	61,856	57,951	57,967	53,764	53,628	19,307	267
Shares Outstanding	0.1%	1,042	1,042	1,042	1,307	1,306	1,302	1,327	1,161	1,150	1,150	422	373
Float	-	-	-	-	10,500	-	-	-	19,400	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-31.2%	-4,321	-3,294	-3,237	-3,079	-3,202	-3,185	-4,621	-1,935	-2,152	-1,744	-548	-499	-381	-	-
Share Based Compensation	395.4%	346	70.00	127	219	177	156	-16.07	559	136	-	-	-	-	-	-
Cashflow From Investing	-100.0%	-	55.00	50.00	24.00	-53.89	-2,341	-25.97	70.00	-1.95	-	-	-	-	-	-
Cashflow From Financing	-	-	-	-3,859	-130	264	-	-	-	-	34,165	20,555	-	1,209	-	-
Buy Backs	-	-	-	3,726	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KTTA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
General and administrative	$ 2,291,646	$ 2,116,266
Research and development	1,749,128	1,096,286
Loss from operations	(4,040,774)	(3,212,552)
Other income:
Change in fair value of warrant liabilities	26,716	(46,870)
Interest and dividends, net	153,218	(6,388)
Other income (expense), net	179,934	(53,258)
Loss before income taxes	(3,860,840)	(3,265,810)
Provision for income taxes
Net loss from continuing operations	(3,860,840)	(3,265,810)
Net loss from discontinued operations, net of tax		(271,869)
Net loss	$ (3,860,840)	$ (3,537,679)
Weighted-average common shares outstanding, basic (in Shares)	1,042,479	1,303,652
Basic loss per share from continuing operations (in Dollars per share)	$ (3.7)	$ (2.6)
Basic loss per share from discontinuing operations (in Dollars per share)		$ (0.2)
Comprehensive loss:
Net loss	$ (3,860,840)	$ (3,537,679)
Foreign currency translation	(620)	(2,483)
Comprehensive loss	$ (3,861,460)	$ (3,540,162)

KTTA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 12,009,347	$ 16,331,052
Amount due from sale of assets	40,500	40,500
Prepaid expenses	1,038,402	215,895
Other current assets	104,649	104,707
Total current assets	13,192,898	16,692,154
Property and equipment, net	136,491	141,208
Right of use asset- operating lease	32,026	79,271
Intangibles, net	7,783,773	7,941,314
Goodwill	1,262,911	1,262,911
Total assets	22,408,099	26,116,858
Current liabilities:
Accounts payable and accrued liabilities	2,433,991	2,552,360
Lease liability- short term portion	32,989	81,680
Total current liabilities	2,466,980	2,634,040
Non-current liabilities
Warrant liabilities	57,650	84,366
Total non-current liabilities	57,650	84,366
Total liabilities	2,524,630	2,718,406
Stockholders’ equity:
Preferred stock, par value $0.0001, 5,000,000 shares authorized; 0 issued and outstanding
Common stock, par value $0.0001, 100,000,000 shares authorized; 1,043,248 and 1,041,582 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	104	104
Additional paid-in capital	59,068,015	58,721,538
Accumulated other comprehensive loss	(5,272)	(4,652)
Accumulated deficit	(39,179,378)	(35,318,538)
Total stockholders’ equity	19,883,469	23,398,452
Total liabilities and stockholders’ equity	$ 22,408,099	$ 26,116,858

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

CEO	Dr. Tiago Reis Marques M.D., Ph.D.
WEBSITE	pasithea.com
INDUSTRY	Biotechnology
EMPLOYEES	15

Pasithea Therapeutics Corp. Frequently Asked Questions

What is the ticker symbol for Pasithea Therapeutics Corp.? What does KTTA stand for in stocks?

KTTA is the stock ticker symbol of Pasithea Therapeutics Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pasithea Therapeutics Corp. (KTTA)?

As of Thu May 16 2024, market cap of Pasithea Therapeutics Corp. is 6.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KTTA stock?

You can check KTTA's fair value in chart for subscribers.

What is the fair value of KTTA stock?

You can check KTTA's fair value in chart for subscribers. The fair value of Pasithea Therapeutics Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pasithea Therapeutics Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KTTA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pasithea Therapeutics Corp. a good stock to buy?

The fair value guage provides a quick view whether KTTA is over valued or under valued. Whether Pasithea Therapeutics Corp. is cheap or expensive depends on the assumptions which impact Pasithea Therapeutics Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KTTA.

What is Pasithea Therapeutics Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, KTTA's PE ratio (Price to Earnings) is -0.42 and Price to Sales (PS) ratio is 16.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KTTA PE ratio will change depending on the future growth rate expectations of investors.